(object) array( 'id' => '10479591', 'url' => 'FR/actinic_keratoses_₂', 'image' => '', 'title' => 'Kératose actinique', 'tags' => array ( 0 => 'Kératose actinique', 1 => 'Beauty', 2 => 'Skin care', 3 => '', ), 'term' => 'Kératose actinique', 'source_id' => 5092398, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Beauty', ), 'category' => array ( 0 => 'Skin care', ), 'lastedit' => '20150728083418', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Lésions précancéreuses se traduisant par une zone rouge, épaisse et rugueuse ; elles apparaissent habituellement sur une peau endommagée par le soleil.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507928310838984706, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Definition' => 'Precancerous growths that can appear red, thick, and rough; usually found on sun-damaged skin.', 'Part of Speech' => 'noun', 'Industry' => 'Beauty', 'Product Category' => 'Skin care', 'Creation User' => 'MaryK', 'Creation Date' => '2013/3/15', 'Term' => 'actinic keratoses', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'actinic_keratoses_₂', )

(object) array( 'id' => '7745840', 'url' => 'FR/experimental_treatment', 'image' => '', 'title' => 'Traitement expérimental', 'tags' => array ( 0 => 'Traitement expérimental', 1 => 'Pharmaceutical', 2 => 'Clinical trials', 3 => '', ), 'term' => 'Traitement expérimental', 'source_id' => 1259724, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'lastedit' => '20150721084114', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Le nouveau médicament ou thérapie testé dans l\'essai clinique.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507294573052821507, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'experimental treatment', 'Definition' => 'The new drug or therapy being tested in the clinical trial.', 'Part of Speech' => 'noun', 'Usage Status' => 'New', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Clinical trials', 'Creation User' => 'John Martin', 'Creation Date' => '2011/5/16', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'experimental_treatment', )

(object) array( 'id' => '6228059', 'url' => 'FR/single_blind_masking', 'image' => '', 'title' => 'Etude en simple aveugle', 'tags' => array ( 0 => 'Etude en simple aveugle', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Etude en simple aveugle', 'source_id' => 4011054, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150722105915', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Un type d\'étude en aveugle dans laquelle une partie impliquée dans l\'essai clinique, soit l\'investigateur soit le participant, ne sait pas à quels participants ont été assignées quelles interventions.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851745107970, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'A type of masking in which one party involved with the clinical trial, either the investigator or participant, does not know which participants have been assigned which interventions.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'single blind masking', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'single_blind_masking', )

(object) array( 'id' => '8442002', 'url' => 'FR/thiomersal', 'image' => 'Vaccines with thiomersal.jpg;', 'title' => 'Thiomersal', 'tags' => array ( 0 => 'Thiomersal', 1 => 'Pharmaceutical', 2 => 'Vaccines', 3 => '', ), 'term' => 'Thiomersal', 'source_id' => 274263, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Vaccines', ), 'lastedit' => '20150721084102', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Le thimérosal est un conservateur contenant du mercure qui est souvent utilisé dans les vaccins en raison de ses propriétés antiseptiques et antifongiques. L\'utilisation du thimérosal comme conservateur de vaccin a été controversée au cours des dernières années en raison du risque potentiellement accru de provoquer l\'autisme chez les enfants. Cependant, la dernière étude du CDC a toutefois montré qu\'aucun lien n\'avait été trouvé entre le thimérosal et l\'autisme.', 'usage_comment' => '', 'glossary' => '', 'width' => 485, 'height' => 385, '_version_' => 1507294573052821508, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'thiomersal', 'Definition' => 'Thimerosal is a mercury-based preservative that is often used in vaccines because of its antiseptic and antifungal properties. The use of thimerosal as a vaccine preservative has been controversial in recent years due to potentially increased risk of causing children\'s autism. However, the latest CDC study however showed no link found between thimerosal and autism', 'Part of Speech' => 'noun', 'Usage Status' => 'New', 'Synonym' => '', 'Sample Image' => 'Vaccines with thiomersal.jpg;', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Vaccines', 'Domain' => 'Documentation; Marketing', 'Other Reference' => 'TIN', 'Creation User' => 'Williamb', 'Creation Date' => '2010/9/13', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'thiomersal', )

(object) array( 'id' => '7155228', 'url' => 'FR/drug_₇', 'image' => '', 'title' => 'Médicament', 'tags' => array ( 0 => 'Médicament', 1 => 'Pharmaceutical', 2 => 'Drugs', 3 => '', ), 'term' => 'Médicament', 'source_id' => 3211237, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Drugs', ), 'lastedit' => '20150721112812', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Une substance qui est prise à l\'intérieur ou mise sur le corps, car elle peut tuer les germes ou modifier la façon dont le corps fonctionne.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507305079943725057, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'drug', 'Definition' => 'A substance that is taken into or put on the body because it can kill germs or change how the body works.', 'Part of Speech' => 'noun', 'Usage Status' => 'New', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Drugs', 'Creation User' => 'tahira rafiq', 'Creation Date' => '2012/6/18', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'drug_₇', )

(object) array( 'id' => '6227765', 'url' => 'FR/inclusion_criteria', 'image' => '', 'title' => 'Critères d\'inclusion', 'tags' => array ( 0 => 'Critères d\'inclusion', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Critères d\'inclusion', 'source_id' => 4010895, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150722105913', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Les facteurs ou les raisons qui autorisent une personne à participer à une étude clinique.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851745107969, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'The factors or reasons that allow a person to participate in a clinical study.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'inclusion criteria', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'inclusion_criteria', )

(object) array( 'id' => '6229325', 'url' => 'FR/informed_consent_₁₂', 'image' => '', 'title' => 'Consentement éclairé', 'tags' => array ( 0 => 'Consentement éclairé', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Consentement éclairé', 'source_id' => 4011444, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150727104711', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Un processus dans lequel les chercheurs communiquent avec les participants potentiels et inscrits dans une étude clinique. Ceci est lorsque les chercheurs : # fournissent toutes les informations importantes concernant l\'étude, de sorte que les participants potentiels peuvent décider de s\'y inscrire (ou si elles sont inscrites, de continuer à participer) ; # s\'assurent que les participants potentiels comprennent les risques et les bénéfices potentiels de participer à l\'étude, et les alternatives à l\'étude conduite ; et # soulignent que l\'inscription à une étude clinique (et de rester dedans) est entièrement volontaire. Parce que donner son consentement pour participer à la recherche n\'est pas un contrat, les participants peuvent quitter une étude à tout moment. Le but du processus de consentement éclairé est de protéger les participants. Il commence quand un participant potentiel demande au début des informations sur une étude et continue tout au long de l\'étude jusqu\'à ce que l\'étude se termine. Le chercheur et le participant potentiel ont des discussions qui incluent de répondre aux questions des participants sur la recherche. Toutes les informations importantes à propos de l\'étude doivent également être remises au participant potentiel dans un document écrit qui est clair et facile à comprendre. Ce document de consentement éclairé est examiné et approuvé par le Comité de protection des personnes pour chaque étude avant d\'être remis aux participants potentiels. Généralement, une personne doit signer un document de consentement éclairé pour s\'inscrire dans une étude.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507846081754431490, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'A process in which researchers communicate with potential and enrolled participants about a clinical study. This is when researchers: # provide all the important information about the study, so that potential participants can decide whether to enroll (or if enrolled, to continue participating); # ensure that potential participants understand the risks and potential benefits of participating in the study, and the alternatives to the research being conducted; and # stress that enrolling in (and staying in) a clinical study is completely voluntary. Because giving consent to participate in research is not a contract, participants can leave a study at any time. The goal of the informed consent process is to protect participants. It begins when a potential participant first asks for information about a study and continues throughout the study until the study ends. The researcher and potential participant have discussions that include answering the participant\'s questions about the research. All the important information about the study must also be given to the potential participant in a written document that is clear and easy to understand. This informed consent document is reviewed and approved by the human subjects review board for a study before it is given to potential participants. Generally, a person must sign an informed consent document to enroll in a study.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'informed consent', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'informed_consent_₁₂', )

(object) array( 'id' => '6229091', 'url' => 'FR/study_design', 'image' => '', 'title' => 'Plan d\'étude', 'tags' => array ( 0 => 'Plan d\'étude', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Plan d\'étude', 'source_id' => 4011443, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150727104709', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Les méthodes d\'investigation utilisées dans l\'étude clinique. Pour les études interventionnelles, celles-ci incluent un objectif principal, un modèle d\'intervention, en insu ou en aveugle, et une affectation.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507846081754431489, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'The investigative methods used in the clinical study. For interventional studies, these include primary purpose, intervention model , masking or blinding, and allocation.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'study design', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'study_design', )

(object) array( 'id' => '6229090', 'url' => 'FR/comparison_group_₂', 'image' => '', 'title' => 'Groupe de comparaison', 'tags' => array ( 0 => 'Groupe de comparaison', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Groupe de comparaison', 'source_id' => 4011326, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150727104707', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Un groupe de participants à une étude clinique qui est utilisé pour synthétiser les données recueillies lors de l\'étude. Ce groupe peut être identique ou différent d\'un bras de l\'étude.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507846081754431488, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'A grouping of participants in a clinical study that is used in summarizing the data collected during the study. This grouping may be the same as or different from a study arm.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Synonym' => 'reporting_group', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'comparison group', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'comparison_group_₂', )

(object) array( 'id' => '10479588', 'url' => 'FR/Dermokil', 'image' => 'dermokillogo-1359898176.jpg;', 'title' => 'Dermokil', 'tags' => array ( 0 => 'Dermokil', 1 => 'Beauty', 2 => 'Skin care', 3 => '', ), 'term' => 'Dermokil', 'source_id' => 4925105, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Beauty', ), 'category' => array ( 0 => 'Skin care', ), 'lastedit' => '20150728083408', 'part_of_speech' => 'proper noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Ezel Kozmetik a été fondée suite à une décision prise par l’homme d’affaire Ünal Karaca après avoir vu que l’on pouvait concevoir des produits cosmétiques à partir de sel de la mer Morte. Sur ce, il décida de produire des produits à base d\'argile qui sont utilisés depuis des siècles en Anatolie et plus récemment partout dans le monde et de promouvoir ses avantages en tant que produits cosmétiques. Les produits Dermokil (Produits Dermoclay) ont vu le jour à l’issue de 2 ans d’étude dans les laboratoires R&D et après les résultats positifs obtenus lors des essais effectués sur 2000 personnes. Les certificats d’enregistrement de marque et les rapports d’approbation établis par l’université Cumhuriyet, les matières premières et les produits ayant des rapports d’analyse microbiologique sont contrôlés par des dispositifs technologiques conformément aux normes nationales et internationales. Les analyses physiques, chimiques et microbiologiques des produits se réalisent d’une manière rapide et sûre à chaque étape de la production. L\'usine d\'Ezel Kozmetik composée d\'installations de production modernes a été établie à Sivas en 2006 et d\'une équipe de R&D composée d’ingénieurs chimistes experts en la matière, vise à devenir une marque leader dans le secteur de la cosmétique à travers ses machines de technologie avancée et son service logistique.', 'usage_comment' => '', 'glossary' => '', 'width' => 300, 'height' => 300, '_version_' => 1507928310837936128, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'Dermokil', 'Definition' => 'Ezel Kozmetik was founded when Unal Karaca, the businessman, saw that the cosmetic products were made up of the salt of the Dead Sea and decided to produce the clay products which have been used in Anatolia for centuries and throughout the world during the recent years and to promote its benefits as a cosmetics. The Dermokil products (Dermoclay Products) appeared after testing on 2000 individuals and obtaining positive results and a two-year R&D study. Its brand registration certificates and the reports approved by Cumhuriyet University, the raw materials and products having microbiological analysis report are inspected by technological devices in national and international standards. In every stage of the production, the physical, chemical and microbiological analyses of the products are rapidly and reliably conducted. The factory of Ezel Kozmetik composed of the modern manufacturing plant established in Sivas in 2006 and an R&D team consisting of chemical engineers who are expert in their field aims to go ahead on the road to become a pioneer brand in the cosmetics sector through the high-tech machines and logistics services it provides.', 'Part of Speech' => 'proper noun', 'Usage Status' => 'New', 'Sample Image' => 'dermokillogo-1359898176.jpg;', 'Industry' => 'Beauty', 'Product Category' => 'Skin care', 'Creation User' => 'dermokil', 'Creation Date' => '2013/2/5', 'Company' => '', 'Synonym' => '', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'Dermokil', )